<p>NewcelX AG has appointed Prof. Jeremy Shefner, MD, PhD, as a member of its Scientific Advisory Board. Prof. Shefner will provide strategic guidance for the company’s ALS programs and support the integration of neuromuscular and neurodegenerative disease expertise into NewcelX’s cell therapy and neuroscience platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-111253), on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

NCEL

<p>NewcelX AG has appointed Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. He will provide strategic guidance for ALS programs and support the integration of neuromuscular and neurodegenerative disease expertise into NewcelX’s cell therapy and neuroscience platform.</p>

NewcelX Appoints Jeremy Shefner to Scientific Advisory Board